Although IgE blockade is a viable therapeutic approach for IgE-mediated allergies, the most widely prescribed treatment is omalizumab, whose efficacy is limited for patients with high lgE levels and safety is suboptimal due to its risk of anaphylaxis. This evidence concerns the gene IGHE and anaphylaxis.